Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor–Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial Metastatic ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Combining olaparib (Lynparza) with abiraterone acetate (Zytiga) as first-line therapy for biomarker-selected patients with metastatic castration-resistant prostate cancer significantly improved ...

This trial of 81 men with mCRPC determined the radiographic progression-free survival (rPFS), prostate-specific antigen (PSA) progression-free survival, overall objective response, and safety of AAP ...

The US Food and Drug Administration (FDA) has approved niraparib and abiraterone acetate (Akeega, Janssen Pharmaceuticals) to treat BRCA-positive, metastatic castration-resistant prostate cancer in ...

Please provide your email address to receive an email when new articles are posted on . Two years of abiraterone acetate plus prednisolone-based therapy significantly improved survival among men with ...

The addition of abiraterone acetate (Zytiga) to standard therapy with docetaxel plus androgen deprivation therapy (ADT) significantly improved overall survival in patients with de novo metastatic ...

BEERSE, Belgium--(BUSINESS WIRE)--The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines ...

LOUISVILLE, Ky--(BUSINESS WIRE)--Onco360 ®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by The Janssen Pharmaceutical Companies of Johnson & Johnson ...

Results of a phase 3 trial published in The Lancet Oncology have confirmed that the drug abiraterone acetate (marketed as Zytiga®) offers a significant survival benefit to patients with ...

In patients with BRCA2-mutated mCSPC, treatment with Akeega significantly reduced the risk of radiographic progression or death by 54%. The Food and Drug Administration (FDA) has approved Akeega ® ...